Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients

References

• World Health Organization. Chronic obstructive pulmonary disease (COPD). Available from: http://www.who.int/mediacentre/factsheets/fs315/en/ Accessed 219, 2018.
   Google Scholar
• Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931–1940. doi:10.1016/S0140-6736(17)31222-928513453
   PubMed Web of Science ®Google Scholar
• Bidan CM, Veldsink AC, Meurs H, Gosens R. Airway and extracellular matrix mechanics in COPD. Front Physiol. 2015;6:346. doi:10.3389/fphys.2015.0034626696894
   PubMed Web of Science ®Google Scholar
• Casaburi R. Activity promotion: a paradigm shift for chronic obstructive pulmonary disease therapeutics. Proc Am Thorac Soc. 2011;8(4):334–337. doi:10.1513/pats.201101-001RM21816989
   PubMedGoogle Scholar
• Corbridge SJ, Nyenhuis SM. Promoting physical activity and exercise in patients with asthma and chronic obstructive pulmonary disease. J Nurse Pract. 2017;13(1):41–46. doi:10.1016/j.nurpra.2016.08.022
   Google Scholar
• Troosters T, Sciurba F, Battaglia S, et al. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir Med. 2010;104(7):1005–1011. doi:10.1016/j.rmed.2010.01.01220167463
   PubMed Web of Science ®Google Scholar
• Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur Respir J. 2009;33(2):262–272. doi:10.1183/09031936.0002460819010994
   PubMed Web of Science ®Google Scholar
• Gea J, Pascual S, Casadevall C, Orozco-Levi M, Barreiro E. Muscle dysfunction in chronic obstructive pulmonary disease: update on causes and biological findings. J Thorac Dis. 2015;7(10):E418–E438.26623119
   PubMed Web of Science ®Google Scholar
• Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Quantifying physical activity in daily life with questionnaires and motion sensors in COPD. Eur Respir J. 2006;27(5):1040–1055. doi:10.1183/09031936.06.0006410516707399
   PubMed Web of Science ®Google Scholar
• Ding B, Small M, Bergstrom G, Holmgren U. COPD symptom burden: impact on health care resource utilization, and work and activity impairment. Int J Chron Obstruct Pulmon Dis. 2017;12:677–689. doi:10.2147/COPD.S12389628260874
   PubMed Web of Science ®Google Scholar
• Laurin C, Moullec G, Bacon SL, Lavoie KL. Impact of anxiety and depression on chronic obstructive pulmonary disease exacerbation risk. Am J Respir Crit Care Med. 2012;185(9):918–923. doi:10.1164/rccm.201105-0939PP22246177
   PubMed Web of Science ®Google Scholar
• Giardino ND, Curtis JL, Andrei AC, et al. Anxiety is associated with diminished exercise performance and quality of life in severe emphysema: a cross-sectional study. Respir Res. 2010;11:29. doi:10.1186/1465-9921-11-2920214820
   PubMed Web of Science ®Google Scholar
• Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(9):972–977. doi:10.1164/rccm.200407-855OC15665324
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2018 report. Available from: https://goldcopd.org/gold-reports/ Accessed 717, 2018.
   Google Scholar
• O’Donnell DE, Casaburi R, Frith P, et al. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. Eur Respir J. 2017;49(4):1601348. doi:10.1183/13993003.01348-201628424359
   PubMed Web of Science ®Google Scholar
• Thomas M, Decramer M, O’Donnell DE. No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J. 2013;22(1):101–111. doi:10.4104/pcrj.2013.0002523429861
   PubMedGoogle Scholar
• O’Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832–840. doi:10.1183/09031936.04.0011600415218994
   PubMed Web of Science ®Google Scholar
• O’Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(2):180–184. doi:10.1513/pats.200508-093DO16565429
   PubMedGoogle Scholar
• Maltais F, O’Donnell D, Galdiz Iturri JB, et al. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2018;12:1–13. doi:10.1177/1753465818755091
   Web of Science ®Google Scholar
• Troosters T, Maltais F, Leidy N, et al. Effect of bronchodilation, exercise training, and behavior modification on symptoms and physical activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(8):1021–1032. doi:10.1164/rccm.201706-1288OC29664681
   PubMed Web of Science ®Google Scholar
• Peeters G, Dobson A, Deeg D, Brown W. A life-course perspective on physical functioning in women. Bull World Health Organ. 2013;91(9):661–670. doi:10.2471/BLT.13.12307524101782
   PubMed Web of Science ®Google Scholar
• Sauer R, Hansel M, Buhl R, Rubin RA, Frey M, Glaab T. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study. Int J Chron Obstruct Pulmon Dis. 2016;11:891–898.27217742
   PubMed Web of Science ®Google Scholar
• Steinmetz K, Abenhardt B, Pabst S, et al. Physical functioning, general condition and satisfaction with tiotropium/olodaterol in real-world COPD patients in Germany. Abstract submitted to European Respiratory Society International Congress; 2018; Paris.
   Google Scholar
• Boehringer Ingelheim Limited. Spiolto Respimat 2.5 microgram/2.5 microgram, inhalation solution – summary of product characteristics. Available from: https://www.medicines.org.uk/emc/medicine/30495 Accessed 228, 2018.
   Google Scholar
• Hassan E. Recall bias can be a threat to retrospective and prospective research designs. Internet J Epidemiol. 2018;3(2):4.
   Google Scholar
• Althubaiti A. Information bias in health research: definition, pitfalls, and adjustment methods. J Multidiscip Healthc. 2016;9:211–217. doi:10.2147/JMDH.S10480727217764
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483. doi:10.1097/00005650-199206000-000021593914
   PubMed Web of Science ®Google Scholar
• Cohen J, editor. Statistical Power Analysis for the Behavioral Sciences. 1st ed. Hillsdale (NJ): Lawrence Erlbaum Associates Inc.; 1977.
   Google Scholar
• Steinmetz K, Abenhardt B, Pabst S, et al. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting. Int J Chron Obstruct Pulmon Dis. 2019;14:1441–453. doi:10.2147/COPD.S195852
   Web of Science ®Google Scholar
• Rau-Berger H, Mitfessel H, Glaab T. Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2010;5:367–373. doi:10.2147/COPD.S1408221103403
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease. GOLD 2017: global strategy for the diagnosis, management and prevention of COPD - Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/ Accessed 96, 2017.
   Google Scholar
• Esteban C, Quintana JM, Aburto M, et al. Impact of changes in physical activity on health-related quality of life among patients with COPD. Eur Respir J. 2010;36(2):292–300. doi:10.1183/09031936.0002140920075059
   PubMed Web of Science ®Google Scholar
• Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140(2):331–342. doi:10.1378/chest.10-252121273294
   PubMed Web of Science ®Google Scholar
• Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45(4):969–979. doi:10.1183/09031936.0013601425573406
   PubMed Web of Science ®Google Scholar
• Beeh KM, Westerman J, Kirsten AM, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;32:53–59. doi:10.1016/j.pupt.2015.04.00225956072
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158(5):1557–1565. doi:10.1164/ajrccm.158.5.98040049817708
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Hamilton AL, Webb KA. Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD. J Appl Physiol. 2006;101(4):1025–1035. doi:10.1152/japplphysiol.01470.200516675610
   PubMed Web of Science ®Google Scholar
• Hohlfeld JM, Vogel-Claussen J, Biller H, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018;6(5):368–378. doi:10.1016/S2213-2600(18)30054-729477448
   PubMed Web of Science ®Google Scholar
• Ichinose M, Minakata Y, Motegi T, et al. Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity. Int J Chron Obstruct Pulmon Dis. 2018;13:1407–1419. doi:10.2147/COPD.S16602329750027
   PubMed Web of Science ®Google Scholar
• Zwerink M, van der Palen J, van der Valk P, Brusse-Keizer M, Effing T. Relationship between daily physical activity and exercise capacity in patients with COPD. Respir Med. 2013;107(2):242–248. doi:10.1016/j.rmed.2012.09.01823085213
   PubMed Web of Science ®Google Scholar
• Shioya T, Sato S, Iwakura M, et al. Improvement of physical activity in chronic obstructive pulmonary disease by pulmonary rehabilitation and pharmacological treatment. Respir Investig. 2018;56(4):292–306. doi:10.1016/j.resinv.2018.05.002
   PubMed Web of Science ®Google Scholar
• Borel B, Provencher S, Saey D, Maltais F. Responsiveness of various exercise-testing protocols to therapeutic interventions in COPD. Pulm Med. 2013;2013:410748. doi:10.1155/2013/41074823431439
   PubMedGoogle Scholar
• Bourbeau J, Lavoie KL, Sedeno M. Comprehensive self-management strategies. Semin Respir Crit Care Med. 2015;36(4):630–638. doi:10.1055/s-0000007526238647
   PubMed Web of Science ®Google Scholar
• Celli B, Blasi F, Gaga M, et al. Perception of symptoms and quality of life – comparison of patients’ and physicians’ views in the COPD MIRROR study. Int J Chron Obstruct Pulmon Dis. 2017;12:2189–2196. doi:10.2147/COPD.S13671128794623
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18(1):67. doi:10.1186/s12931-017-0548-328431503
   PubMed Web of Science ®Google Scholar
• ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies. Int J Chron Obstruct Pulmon Dis. 2014;9:1133–1144. doi:10.2147/COPD.S7248225342898
   PubMed Web of Science ®Google Scholar
• White DK, Wilson JC, Keysor JJ. Measures of adult general functional status: SF-36 Physical Functioning Subscale (PF-10), Health Assessment Questionnaire (HAQ), Modified Health Assessment Questionnaire (MHAQ), Katz Index of Independence in activities of daily living, Functional Independence Measure (FIM), and Osteoarthritis-Function-Computer Adaptive Test (OA-Function-CAT). Arthritis Care Res. 2011;63 Suppl 11:S297–S307.
   Web of Science ®Google Scholar
• Eisner MD, Blanc PD, Yelin EH, et al. COPD as a systemic disease: impact on physical functional limitations. Am J Med. 2008;121(9):789–796. doi:10.1016/j.amjmed.2008.04.03018724969
   PubMed Web of Science ®Google Scholar
• Holt S, Sheahan D, Helm C, Tofield C, Corin A, Kocks JW. Little agreement in GOLD category using CAT and mMRC in 450 primary care COPD patients in New Zealand. NPJ Prim Care Respir Med. 2014;24:14025. doi:10.1038/npjpcrm.2014.2525056446
   PubMed Web of Science ®Google Scholar
• Kim S, Oh J, Kim YI, et al. Differences in classification of COPD group using COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores: a cross-sectional analyses. BMC Pulm Med. 2013;13:35. doi:10.1186/1471-2466-13-3523731868
   PubMed Web of Science ®Google Scholar
• Davis KJ, Landis SH, Oh YM, et al. Continuing to Confront COPD International Physician Survey: physician knowledge and application of COPD management guidelines in 12 countries. Int J Chron Obstruct Pulmon Dis. 2014;10:39–55.25565799
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Andreu I, Romero Y, Sitjar S, Altes A, Anton E. Difficulties in differential diagnosis of COPD and asthma in primary care. Br J Gen Pract. 2012;62(595):e68–e75. doi:10.3399/bjgp12X62511122520766
   PubMed Web of Science ®Google Scholar
• Bjornsdottir US, Sigurethardottir ST, Jonsson JS, et al. Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting beta(2) -agonists in obstructive lung diseases: a population-based, observational study. Int J Clin Pract. 2014;68(7):812–819. doi:10.1111/ijcp.1247324942308
   PubMed Web of Science ®Google Scholar
• Anzueto AR, Vogelmeier CF, Kostikas K, et al. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1325–1337. doi:10.2147/COPD.S13330728496316
   PubMed Web of Science ®Google Scholar
• Greulich T, Kostikas K, Gaga M, et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. Int J Chron Obstruct Pulmon Dis. 2018;13:1229–1237. doi:10.2147/COPD.S15973229713156
   PubMed Web of Science ®Google Scholar
• Anzueto AR, Kostikas K, Mezzi K, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study. Respir Res. 2018;19(1):121. doi:10.1186/s12931-018-0830-z29925383
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Braido F, et al. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:3115–3130. doi:10.2147/COPD.S17060630323582
   PubMed Web of Science ®Google Scholar
• Alahmari AD, Kowlessar BS, Patel AR, et al. Physical activity and exercise capacity in patients with moderate COPD exacerbations. Eur Respir J. 2016;48(2):340–349. doi:10.1183/13993003.01105-201527126688
   PubMed Web of Science ®Google Scholar
• Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Physical activity and hospitalization for exacerbation of COPD. Chest. 2006;129(3):536–544. doi:10.1378/chest.129.3.53616537849
   PubMed Web of Science ®Google Scholar
• Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax. 2006;61(9):772–778. doi:10.1136/thx.2006.06014516738033
   PubMed Web of Science ®Google Scholar
• Jones GL. Quality of life changes over time in patients with chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2016;22(2):125–129. doi:10.1097/MCP.000000000000024226814143
   PubMed Web of Science ®Google Scholar
• Beeh KM, Burgel PR, Franssen FME, et al. How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2017;196(2):139–149. doi:10.1164/rccm.201609-1794CI27922741
   PubMed Web of Science ®Google Scholar
• Ariel A, Altraja A, Belevskiy A, et al. Inhaled therapies in patients with moderate COPD in clinical practice: current thinking. Int J Chron Obstruct Pulmon Dis. 2017;13:45–56. doi:10.2147/COPD.S14557329317810
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa151638527181606
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. FDA approves Stiolto® Respimat® supplemental New Drug Application (sNDA) to add data on COPD exacerbation reduction. Available from: https://www.boehringer-ingelheim.us/press-release/fda-approves-stiolto-respimat-supplemental-new-drug-application-snda-add-data-copd Accessed 119, 2018.
   Google Scholar
• Sievi NA, Brack T, Brutsche MH, et al. Accelerometer- versus questionnaire-based assessment of physical activity and their changes over time in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1113–1118. doi:10.2147/COPD.S13019528435244
   PubMed Web of Science ®Google Scholar
• Thyregod M, Bodtger U. Coherence between self-reported and objectively measured physical activity in patients with chronic obstructive lung disease: a systematic review. Int J Chron Obstruct Pulmon Dis. 2016;11:2931–2938. doi:10.2147/COPD.S11642227932873
   PubMed Web of Science ®Google Scholar
• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887–1892. doi:10.1056/NEJM20000622342250710861325
   PubMed Web of Science ®Google Scholar